| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 209.3 | 187.8 |
| Gross profit | 96.6 | 80.4 |
| Profit before tax | -8.0 | -26.4 |
| Net income | -7.5 | -27.1 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +11.4% |
|---|---|
| Gross margin | 46.2% |
| Operating margin | -3.8% |
10-Q filed with the SEC, NASDAQ: NEO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Neogenomics Inc: key numbers
- Share price
- $15.41Close, Nov 16
- Market cap
- $1.99B
- Shares outstanding
- 129.39MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Testing LaboratoriesSIC 8734
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Neogenomics Inc
All →Neogenomics Financial Results
NeoGenomics reported third-quarter 2026 revenue of $209 million, an 11% year-over-year increase driven by 29% growth in Next-Generation Sequencing (NGS) revenue. The company significantly improved its bottom line, reducing its GAAP net loss to $8 million from $27 million in the prior year, and raised its full-year 2026 revenue and adjusted EBITDA guidance.
“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it. Clinical revenue growth of 13% continues to showcase the strength of our broad-based testing solutions portfolio, with NGS revenue growing a strong 29% and NGS test volume growing 17%.”
Tony Zook, Chief Executive Officer of NeoGenomics
Neogenomics Leadership Change
NeoGenomics announced a planned leadership succession where current President and COO Warren Stone will succeed Tony Zook as CEO and join the Board, effective January 4, 2027. Tony Zook will transition to the role of Executive Chairman, while current Board Chair Lynn Tetrault will step down as Chair and not stand for re-election at the 2027 Annual Meeting.